There were 1,857 press releases posted in the last 24 hours and 393,356 in the last 365 days.

Biosimilars Market To Grow At Rate Of 27% With Increasing Prevalence Of Chronic Diseases

Biosimilars Market Report 2021: COVID-19 Growth And Change To 2030

Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, August 3, 2021 / -- Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin.

The major players covered in the global biosimilar drugs market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, and STADA Arzneimittel.

The global biosimilar market size 2020 was $7.49 billion. It is expected to grow to $8.05 billion in 2021 at a compound annual growth rate (CAGR) of 7.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilars market is expected to reach $21.13 billion in 2025 at a CAGR of 27%, The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market.

Read More On The Global Biosimilars Market Report:

The biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceuticals that are manufactured using cell lines and offer no clinical difference as compared to biologics. Biosimilars are made once the patent of biologics is expired.

TBRC’s biosimilars report is segmented by product into recombinant non-glycosylated proteins, recombinant glycosylated proteins; by types into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, others’ by application into oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, others.

Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides biosimilars global market overview, forecast biosimilars global market size and growth for the whole market, biosimilars market segments, and geographies, biosimilars global market trends, biosimilars market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Biosimilars Market Report:

Here Is A List Of Similar Reports By The Business Research Company:

Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth And Change To 2030

Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

Interested to know more about The Business Research Company?
Read more about us at

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The Business Research Company
Follow us on LinkedIn:
Follow us on Twitter:
Check out our Blog:

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
Visit us on social media: